No profile data available.
Regeneron Pharmaceuticals, Inc. (REGN) is a healthcare company in the eye treatment pharmaceuticals industry, based in Tarrytown, United States, with about 15,410 full-time employees.
It reported revenue of $14.34 billion for fiscal year 2025, and net income of $4.50 billion. In Q2 2026 (the quarter ended June 30, 2026) revenue was $4.29 billion. UNITED STATES was its largest region in fiscal year 2025, with 90% of revenue. Its market capitalization was $76.86 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
Regeneron Pharmaceuticals reported $14.34 billion in revenue for fiscal year 2025. In Q2 2026 revenue was $4.29 billion.
UNITED STATES: 90% of revenue by region in fiscal year 2025, followed by Rest Of World (10%).
$76.86 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (eye treatment pharmaceuticals) include Kodiak Sciences Inc. (KOD), Belite Bio, Inc (BLTE), Bausch + Lomb Corporation (BLCO), MeiraGTx Holdings plc (MGTX).